Skip to main content
logo
Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.905
-0.035 (-1.80%)
Oct 8, 2026, 1:09 PM EDT - Market open

Inhibikase Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
34728029081337
Market Cap Growth
137.81%-3.25%3596.14%-37.83%-65.89%-46.68%
Enterprise Value
188203287-9-14-8
Last Close Price
1.942.053.251.273.008.82

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---30.10102.1811.93
PB Ratio
2.211.623.060.710.600.96
P/TBV Ratio
2.231.623.060.710.600.96

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
--0.000.060.020.01
Net Debt / Equity Ratio
-1.04-1.03-1.03-1.15-1.08-1.05
Net Debt / EBITDA Ratio
2.403.903.410.631.25-
Net Debt / FCF Ratio
3.736.435.090.701.292.83
Asset Turnover
---0.010.000.11
Quick Ratio
15.5021.5426.133.856.2510.08
Current Ratio
15.8221.7026.374.136.6010.48
Return on Equity (ROE)
-51.96%-36.05%-52.00%-118.88%-60.74%-61.35%
Return on Assets (ROA)
-32.79%-20.53%-31.60%-63.67%-33.62%-32.24%
Return on Capital Employed (ROCE)
-43.20%-26.60%-30.10%-181.50%-85.30%-38.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-17.76%-17.21%-9.50%-242.67%-143.13%-39.99%
FCF Yield
-12.48%-9.91%-6.61%-230.82%-139.49%-38.66%
Buyback Yield / Dilution
-115.18%-314.60%-293.35%-42.74%-39.15%-121.72%
SEC Filings: 10-K · 10-Q